Medication recommendation system improves safety with clinical evidence

Clinical Evidence-Guided Residual Learning for Medication Recommendation with Dynamic DDI Regularization

Machine LearningInformation Retrieval

Summary

Recommending the right combination of medicines for a patient is hard because some medicines can interact in harmful ways. The authors created EviDrug, a system that learns from clinical evidence and patient history to suggest safer prescriptions. It uses smart ways to understand each patient's needs while reducing risky drug interactions. Their tests showed EviDrug works better and faster than older methods on real hospital data.

What this means in practice

  • For hospital data teams: Deploy patient-specific medication recommendation systems that reduce harmful drug interactions while maintaining accuracy.
  • For clinical decision support developers: Integrate dynamic feedback mechanisms in medication recommendation tools to balance prescription effectiveness with interaction risks.

Authors

Zesheng Li, Chengchang Pan, Honggang Qi

Abstract

Medication recommendation must combine patient-specific treatment evidence with the interaction structure of a prescription. The central challenge is to determine which evidence supports each medication and how strongly to regularize interactions while preserving predictive quality. We propose EviDrug, a clinical evidence-guided residual learning framework. Its clinical-memory backbone integrates a self-trained visit-aware encoder, training-case memory and one medication-set interaction block to establish a patient-specific prescription. A gated refinement head combines the backbone states with clinical associations and history-conditioned medication identities through bounded logit corrections. Drug-drug interaction (DDI) feedback adapts regularization strength using training-query predictions. Across MIMIC-IV, NWICU and SICdb, EviDrug leads twelve published-method baselines in AP, F1 and Jaccard, improving AP by 2.26, 2.06 and 1.71 percentage points over the strongest comparator. These gains come at lower parameter and runtime costs than MetaDrug. Matched controls demonstrate DDI reductions with stable predictive quality. Code is available at https://github.com/LIZESHENG13/EviDrug.